ISS Recommends SomaLogic Stockholders Vote “FOR” Proposed Merger with Standard BioToolsCompany Urges Stockholders to Vote “FOR” Value Maximizing Transaction at Upcoming Special Meeting
SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioToolsCombination Builds Scale and Accelerates Path to Profitability, Unlocking Significant Potential Value for SomaLogic Stockholders
SomaLogic Reports Recent Business Highlights and Third Quarter 2023 Financial ResultsBOULDER, Colo., Nov. 08, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported recent business highlights and financial results for the quarter ended September 30, 2023.
SomaLogic announces new SomaScan® 11K PlatformExpanded menu gives researchers broadest coverage of the proteome for increased discovery of biomarkers and drug targets
SomaLogic to Announce Third Quarter 2023 Financial Results on November 8, 2023BOULDER, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the third quarter 2023 after market close on November 8, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
SomaLogic expands agreement with Novo Nordisk to 2025Novo Nordisk will extend its use of SomaLogic’s innovative proteomics technologies for research in cardiometabolic and other diseases
SomaLogic Reports Second Quarter 2023 Financial ResultsBOULDER, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter ended June 30, 2023.
SomaLogic to Announce Second Quarter 2023 Financial Results on August 14, 2023BOULDER, Colo., July 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the second quarter 2023 after market close on August 14th, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
SomaLogic Partners with Citogen to Expand Authorized Site Program in EuropeSomaLogic’s 7,000-plex SomaScan® Platform will be used in clinical research, population health studies and nutrigenomics.
SomaLogic Announces Chief Financial Officer TransitionAppoints Eliot M. Lurier, CPA, as Interim Chief Financial Officer
SomaLogic to Participate in the Jefferies Healthcare ConferenceBOULDER, Colo., May 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that the company will be participating in the upcoming Jefferies Healthcare Conference.
SomaLogic Reports First Quarter 2023 Financial ResultsBOULDER, Colo., May 11, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter ended March 31, 2023.
SomaLogic expands into China with groundbreaking Biostar Technology Limited PartnershipSomaLogic to deliver 7,000-plex SomaScan® Platform to researchers in attractive Chinese proteomics market
SomaLogic opens their first-ever proteomics grant program to APAC life sciences researchersTwo winners will be awarded 40 human plasma or serum samples to be processed on the SomaScan® Platform at Genomax’s Singapore lab
SomaLogic to Announce First Quarter 2023 Financial Results on May 11, 2023BOULDER, Colo., April 20, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
SomaLogic Reports Fourth Quarter and Full Year 2022 Financial Results, Announces Director Appointments and Management EvolutionBOULDER, Colo., March 28, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today reported financial results for the quarter and year ended December 31, 2022 and announced a management transition, as well as the appointment of four new members to the Board of Directors.
Oxford Population Health and SomaLogic deliver 28 million proteomic data points on China Kadoorie Biobank samplesBOULDER, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay on and delivered data for 4,000 plasma samples from the China Kadoorie Biobank (CKB), one of the world’s largest prospective studies. The SomaLogic team provided more than 28 million data points from the assay which will be combined with other available genetic, lifestyle, anthropometric and health outcome data to address a range of research questions. This work builds on a successful history of SomaScan® Platform utilization in some of the world’s largest population proteomics biobank projects, including the EPIC, MESA, Fenland, Whitehall II, HUNT3, CRIC, COPD Gene, Spiromics, deCODE and ARIC datasets.
SomaLogic to Announce Fourth Quarter and Full Year 2022 Financial ResultsBOULDER, Colo., March 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, March 28, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
